Home / Health / LUNGevity Fights Lung Cancer with Community
LUNGevity Fights Lung Cancer with Community
2 Nov
Summary
- Lung cancer remains leading cause of cancer death in US.
- November events focus on research, early detection, and care.
- Progress offers hope, but accessibility and stigma remain challenges.
This November, LUNGevity Foundation is spearheading Lung Cancer Awareness Month (LCAM) by uniting communities across the United States. The foundation's initiatives aim to translate awareness into tangible action, focusing on critical areas like research, early detection, and enhancing the quality of life for individuals impacted by lung cancer.
Lung cancer continues to be the leading cause of cancer-related deaths in the U.S. Despite significant advances in precision medicine and treatment offering renewed hope, challenges persist. These include ensuring equitable access to new therapies and combating misconceptions and stigma that can hinder timely diagnosis and informed discussions about the disease.
Throughout November, LUNGevity is organizing various opportunities for public engagement. These include the Every Breath Forward℠ movement, featuring a national installation of 60,000 white flags on the National Mall and community sites. Additionally, Breathe Deep TOGETHER events are scheduled in Boston, New York City, and Washington, D.C. on November 7th, with virtual participation options nationwide.
Further initiatives focus on earlier detection and lung cancer screening, particularly around Lung Cancer Screening Day on November 14th. Education on biomarker testing and precision medicine, including LUNGevity's No One Missed campaign, is also a priority, especially in recognition of Cancer Biomarker Awareness Day on November 12th. Advocacy efforts will amplify patient voices to call for sustained research funding and improved policies.
LUNGevity's overarching goal is to accelerate progress in lung cancer research and care, making life-saving advancements accessible to more people. The foundation highlights that finding lung cancer before it spreads significantly improves survival rates, from 29.5% to 65% for 5-year survival.
This year's LCAM efforts are supported by Presenting Sponsor Boehringer Ingelheim and Platinum Sponsors AstraZeneca and Johnson & Johnson, among other key partners. Their contributions are vital to extending awareness, education, research, and community engagement.
